Octreotide inhibits the meal‐induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: A double‐blind, placebo‐controlled study

The aim of this study was to determine the effects of the long‐acting somatostatin analog, octreotide, on portal venous pressure and collateral blood flow in cirrhotic patients with portal hypertension during fasting and postprandial states. In a double‐blind, placebo‐controlled study, we investigated the effects of octreotide on the hepatic venous pressures and azygos blood flow of 21 patients before and after a standard liquid meal containing 40 gm of protein in 250 ml. Octreotide significantly reduced azygos blood flow from a mean of 499 ± 65 ml/min to a mean of 355 ± 47 ml/min (p < 0.01), but it had no effect on the hepatic venous pressure gradient. The hepatic venous pressure gradient of patients in the placebo group increased significantly, from a fasting mean of 16.4 ± 1.6 mm Hg to a mean of 20.0 ± 1.7 mm Hg 30 min after the meal (p < 0.01). In a second protocol hepatic venous pressures were measured in 20 patients at 30‐min intervals for 2 hr after ingestion of the mixed meal. Again the placebo group showed a significant increase in the hepatic venous pressure gradient 30 min after the meal (20.4 ± 1.5 mm Hg vs. 18.2 ± 1.2 mm Hg; p < 0.05), but the group receiving octreotide showed no significant changes during the 2 hr of observation. We conclude that octreotide significantly reduces azygos blood flow, with little effect on portal venous pressure, and that it appears to inhibit postprandial increases in portal pressure in cirrhotic patients with portal hypertension. (HEPATOLOGY 1992;16:1180–1186.)

[1]  P. Pizcueta,et al.  Pathophysiology of portal hypertension. , 1992, Gastroenterology clinics of North America.

[2]  M. Halliwell,et al.  Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man. , 1991, Clinical science.

[3]  A. Burroughs.  Somatostatin and octreotide for variceal bleeding. , 1991, Journal of hepatology.

[4]  F. Moriyasu,et al.  Relationship between esophageal varices and azygos vein evaluated by cineportography , 1991, Hepatology.

[5]  M. Turiel,et al.  [Hemodynamic response to somatostatin at rest and during sympathetic activation in idiopathic orthostatic hypotension]. , 1991, Cardiologia.

[6]  N. Mcintyre,et al.  Octreotide reduces azygos blood flow in cirrhotic patients with portal hypertension , 1990 .

[7]  M. Hughes,et al.  Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. , 1990, Gastroenterology.

[8]  N. Mcintyre,et al.  The effect of non-protein liquid meals on the hepatic venous pressure gradient in patients with cirrhosis. , 1990, Journal of hepatology.

[9]  J. Urrengoetxea,et al.  [Somatostatin and ventricular function in liver cirrhosis]. , 1990, Revista clinica espanola.

[10]  T. Schubert,et al.  A multicenter, randomized, double‐blind trial of somatostatin in the management of acute hemorrhage from esophageal varices , 1989, Hepatology.

[11]  W. Karnes,et al.  Prolonged inhibition of meal‐stimulated acid secretion and gastrin release following single subcutaneous administration of octreotide (SMS 201–995) in man , 1989, Alimentary pharmacology & therapeutics.

[12]  C. Mathias,et al.  The peptide release inhibitor, Octreotide (SMS 201-995), prevents the haemodynamic changes following food ingestion in normal human subjects. , 1989, Quarterly journal of experimental physiology.

[13]  D. Johnston,et al.  Effects of the somatostatin analogue SMS 201-995 (sandostatin) on mouth-to-caecum transit time and absorption of fat and carbohydrates in normal man. , 1988, Clinical science.

[14]  O. Garden,et al.  The effect of a long‐acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis , 1988, Alimentary pharmacology & therapeutics.

[15]  R. Moreau,et al.  Postprandial hemodynamic responses in patients with cirrhosis , 1988, Hepatology.

[16]  A. Hadengue,et al.  Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. , 1988, Gastroenterology.

[17]  R. Casamitjana,et al.  Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. , 1988, The American journal of physiology.

[18]  J. Wahren,et al.  Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. , 1987, Scandinavian journal of gastroenterology.

[19]  T. Adrian,et al.  The effect of a long‐acting somatostatin analogue (SMS 201–995) on intermediary metabolism and gut hormones after a test meal in normal subjects , 1987, Alimentary pharmacology & therapeutics.

[20]  R. G. Long,et al.  Review: long‐acting somatostatin analogues , 1987, Alimentary pharmacology & therapeutics.

[21]  C. Owman,et al.  Contractile and dilatory action of neuropeptides on isolated human mesenteric blood vessels , 1987, Peptides.

[22]  R. Shields,et al.  Effects of a somatostatin analogue SMS 201‐995 on hepatic haemodynamics in the pig and on intravariceal pressure in man , 1985, The British journal of surgery.

[23]  A. J. Premen.  Importance of the liver during glucagon-mediated increases in canine renal hemodynamics. , 1985, The American journal of physiology.

[24]  J. Hall,et al.  Postprandial regulation of renal hemodynamics: role of pancreatic glucagon. , 1985, The American journal of physiology.

[25]  P. Devitt,et al.  A prospective randomised controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal haemorrhage. , 1985, British medical journal.

[26]  R. Groszmann,et al.  Measurement of Azygos Venous Blood Flow by a Continuous Thermal Dilution Technique: An Index of Blood Flow Through Gastroesophageal Collaterals in Cirrhosis , 1984, Hepatology.

[27]  J. Bruix,et al.  Comparison of Intravenous Somatostatin and Vasopressin Infusions in Treatment of Acute Variceal Hemorrhage , 1984, Hepatology.

[28]  C. Mélot,et al.  Effect of vasopressin and somatostatin on hemodynamics and blood gases in patients with liver cirrhosis. , 1982, Critical care medicine.

[29]  C. Mélot,et al.  Effects of vasopressin and somatostatin on hemodynamics and blood gases in patients with liver cirrhosis , 1982 .

[30]  T. Adrian,et al.  The effect of somatostatin analogs on secretion of growth, pancreatic, and gastrointestinal hormones in man. , 1981, The Journal of clinical endocrinology and metabolism.

[31]  J. Bosch,et al.  Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin , 1981 .

[32]  C. E. Wilder,et al.  Catheterization and roentgen visualization of the azygos vein and its tributaries in Laennec's cirrhosis. A new technic. , 1962, Radiology.

[33]  J. L. Brandt,et al.  The effect of oral feedings of meat and glucose on hepatic vein wedge pressure in normal and cirrhotic subjects. , 1958, The Journal of laboratory and clinical medicine.

[34]  S. Siegel,et al.  Nonparametric Statistics for the Behavioral Sciences , 2022, The SAGE Encyclopedia of Research Design.

[35]  Y. Israel,et al.  Ethanol‐induced increase in portal hepatic blood flow: Interference by anesthetic agents , 1987, Hepatology.

[36]  S. Bloom,et al.  Effect of a long-acting somatostatin analogue (SMS 201-995) on postprandial gastric emptying of 99mTc-tin colloid and mouth-to-caecum transit time in man. , 1987, Digestion.

[37]  B. Lembcke,et al.  Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. , 1987, Digestion.

[38]  J. Wahern.  The influence of a Long-acting samatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis , 1986 .

[39]  J. Wahren,et al.  The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. , 1986, Scandinavian journal of gastroenterology. Supplement.

[40]  A. Gatta,et al.  Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension. , 1985, Digestion.

[41]  J. Bosch,et al.  Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. , 1981, Gastroenterology.

[42]  G. Sonnenberg,et al.  Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects. , 1981, Gastroenterology.

[43]  R. Groszmann,et al.  Wedged and free hepatic venous pressure measured with a balloon catheter. , 1979, Gastroenterology.